title: Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.
abstract: BACKGROUND
  For women at potentially increased risk for ovarian cancer, data regarding screening and risk reduction are limited. Previous studies have reported on the behaviors of BRCA mutation carriers, but less is known about the behaviors of non- BRCA carriers. We surveyed a large cohort of women after BRCA testing to identify the prevalence and posttest predictors of risk-reducing and screening interventions.
  
  
  METHODS
  A median of 3.7 years after BRCA testing, 1447 women who received genetic counseling and BRCA testing at 2 hospital sites were surveyed, with a 77.6% response rate. We analyzed data from 1077 survey respondents. We performed univariate and multivariate logistic regression analyses to identify predictors of risk-reducing salpingo-oophorectomy (RRSO), screening transvaginal ultrasonography (TVUS), and screening serum cancer antigen 125 (CA-125).
  
  
  RESULTS
  Among the respondents, 201 women (18.7%) received positive test results for a deleterious mutation, 103 women (9.6%) received true-negative results, and 773 women (71.8%) received uninformative results. Overall, 19.1% of eligible women underwent RRSO and 39.6% used screening procedures. A positive BRCA result predicted RRSO (odds ratio [OR], 28.1; 95% CI, 16.2-48.6), TVUS (9.5 [4.3-21.0]), and serum CA-125 (13.0 [5.5-29.0]). Similarly, a true-negative BRCA result reduced the OR for RRSO (0.1 [0.0-0.6]), TVUS (0.2 [0.1-0.5]), and serum CA-125 (0.3 [0.1-0.7]). Of the 71.8% of women who received uninformative results after BRCA testing, 12.3% subsequently underwent RRSO, 33.8% reported ever having undergone screening serum CA-125 since BRCA testing, and 37.3% reported ever having undergone screening TVUS since BRCA testing.
  
  
  CONCLUSIONS
  Results of BRCA testing strongly predict RRSO and ovarian cancer screening. Use of RRSO and ovarian screening was reported in a sizable percentage of non- BRCA carriers despite insufficient data to determine the effectiveness of these interventions.
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, University of California, San Francisco, 505 Parnassus Ave, Room M1286, San Francisco, CA 94117, USA. Gabriel.mannis@ucsf.edu
authors.forename: Gabriel N
authors.initials: GN
authors.lastname: Mannis
authors.forename: Julia E
authors.initials: JE
authors.lastname: Fehniger
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Creasman
authors.forename: Vanessa L
authors.initials: VL
authors.lastname: Jacoby
authors.forename: Mary S
authors.initials: MS
authors.lastname: Beattie
mesh_terms: D000328:Adult; D018394:CA-125 Antigen / Q000097:blood; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D008403:Mass Screening / Q000706:statistics & numerical data*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000517:prevention & control; D010052:Ovariectomy / Q000706:statistics & numerical data*; D012307:Risk Factors; D058994:Salpingectomy / Q000706:statistics & numerical data*
chemical_list: D018394:CA-125 Antigen